What is UroGen Pharma's stock issuance proceeds?

UroGen Pharma (URGN) reported stock issuance proceeds of $0 in Q1 2026.

How has UroGen Pharma's stock issuance proceeds changed year-over-year?

UroGen Pharma's stock issuance proceeds decreased by 100.0% year-over-year, from $4K to $0.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

UroGen Pharma URGN Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Merck & Co.MRK

$157M+726%

ImmunityBio, Inc.IBRX

$971K+341%

Tyra Biosciences, Inc.TYRA

$147.85M—

CG OncologyCGON

$391.55M+57,312%

Nuvation BioNUVB

$908K-16.1%

ImmunomeIMNM

$229K+7.5%

Other financials

Income statement

See full

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

See full

Market cap$1.73B+71.7%

Enterprise value$1.81B+80.9%

P/S12.3×+1.3×

Profitability

See full

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's stock issuance proceeds?: UroGen Pharma (URGN) reported stock issuance proceeds of $0 in Q1 2026.
How has UroGen Pharma's stock issuance proceeds changed year-over-year?: UroGen Pharma's stock issuance proceeds decreased by 100.0% year-over-year, from $4K to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.